With the advent of personalized medicine, non-genotoxic therapeutic approaches to re-activate p53 in cancer have been subjected to an intense investigation in the last years [130] and several compounds have been studied both in pre-clinical and in clinical trials [18]. This evidence concerns the gene TP53 and cancer.